EP1085859A4 - Traitement des blessures par inhibition d'adenosine diphosphate-ribosyl transferase - Google Patents

Traitement des blessures par inhibition d'adenosine diphosphate-ribosyl transferase

Info

Publication number
EP1085859A4
EP1085859A4 EP99927490A EP99927490A EP1085859A4 EP 1085859 A4 EP1085859 A4 EP 1085859A4 EP 99927490 A EP99927490 A EP 99927490A EP 99927490 A EP99927490 A EP 99927490A EP 1085859 A4 EP1085859 A4 EP 1085859A4
Authority
EP
European Patent Office
Prior art keywords
injury
inhibition
treatment
adenosine diphosphate
ribosyl transferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99927490A
Other languages
German (de)
English (en)
Other versions
EP1085859A1 (fr
Inventor
Samuel J Leibovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Rutgers Health
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of EP1085859A1 publication Critical patent/EP1085859A1/fr
Publication of EP1085859A4 publication Critical patent/EP1085859A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99927490A 1998-06-11 1999-06-11 Traitement des blessures par inhibition d'adenosine diphosphate-ribosyl transferase Withdrawn EP1085859A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8892498P 1998-06-11 1998-06-11
US88924P 1998-06-11
PCT/US1999/013264 WO1999063982A1 (fr) 1998-06-11 1999-06-11 Traitement des blessures par inhibition d'adenosine diphosphate-ribosyl transferase

Publications (2)

Publication Number Publication Date
EP1085859A1 EP1085859A1 (fr) 2001-03-28
EP1085859A4 true EP1085859A4 (fr) 2003-02-26

Family

ID=22214311

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99927490A Withdrawn EP1085859A4 (fr) 1998-06-11 1999-06-11 Traitement des blessures par inhibition d'adenosine diphosphate-ribosyl transferase

Country Status (5)

Country Link
EP (1) EP1085859A4 (fr)
JP (1) JP2002517436A (fr)
AU (1) AU4438399A (fr)
CA (1) CA2329160A1 (fr)
WO (1) WO1999063982A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407676T1 (de) * 2000-02-28 2008-09-15 Univ British Columbia Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
US6538030B2 (en) * 2000-09-20 2003-03-25 Yih-Lin Chung Treating radiation fibrosis
DE10225772A1 (de) * 2002-06-10 2003-12-24 Beiersdorf Ag Kosmetische oder dermatologische Formulierungen zur Pflege der Haut nach einem Sonnenbad oder einer Rasur
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
MX2007012766A (es) 2005-04-12 2008-10-01 Intradigm Corp Composición y métodos de terapéuticos de arni para el tratamiento de cáncer y otras enfermedades de neovascularización.
WO2006113479A2 (fr) * 2005-04-15 2006-10-26 Albert Einstein College Of Medicine Of Yeshiva University Vitamine k destinee a la prevention et au traitement de l'eruption cutanee consequente a une therapie anti-egfr
FR2885802A1 (fr) * 2005-05-17 2006-11-24 Oreal Utilisation cosmetique de la vitamine k pour ameliorer la fonction barriere de la peau
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
EP2712613B1 (fr) * 2012-09-28 2017-02-08 Pharmadab d.o.o. Vitamine K1 et ses utilisations
TWI578994B (zh) * 2014-03-27 2017-04-21 中央研究院 燒燙傷口癒合組合物
WO2025122455A1 (fr) * 2023-12-04 2025-06-12 Invirsa, Inc. Méthodes d'utilisation de la 5'-adénosine diphosphate ribose (adpr) pour la modulation du vegf

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2074627A1 (en) * 1970-01-13 1971-10-08 Socres Ppsoriasis treatment compsn
US4289757A (en) * 1978-02-28 1981-09-15 The Upjohn Company Method for treating inflammation
EP0552439A1 (fr) * 1991-12-02 1993-07-28 VALETUDO S.r.l. Préparations pharmaceutiques à usage topique utilisables dans le traitement du psoriasis et de la dermatite atopique
EP0638309A1 (fr) * 1993-07-14 1995-02-15 ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. Substances inhibant l'adp-ribosylation protéiques appopriées à la prévention des complications du diabète
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
WO1997039733A1 (fr) * 1996-04-23 1997-10-30 The Procter & Gamble Company Methodes de traitement et d'amelioration de l'aspect de la peau au moyen d'un compose a la vitamine b¿3?
WO1997039746A1 (fr) * 1996-04-22 1997-10-30 Advanced Polymer Systems, Inc. Procede et composition servant a traiter des maladies de la peau au moyen de vitamine k

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029770A (en) * 1974-03-26 1977-06-14 Caw Industries, Inc. Method of therapeutically treating damaged and/or infected tissue and relieving stress and shock in warm blooded animals

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2074627A1 (en) * 1970-01-13 1971-10-08 Socres Ppsoriasis treatment compsn
US4289757A (en) * 1978-02-28 1981-09-15 The Upjohn Company Method for treating inflammation
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
EP0552439A1 (fr) * 1991-12-02 1993-07-28 VALETUDO S.r.l. Préparations pharmaceutiques à usage topique utilisables dans le traitement du psoriasis et de la dermatite atopique
EP0638309A1 (fr) * 1993-07-14 1995-02-15 ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. Substances inhibant l'adp-ribosylation protéiques appopriées à la prévention des complications du diabète
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
WO1997039746A1 (fr) * 1996-04-22 1997-10-30 Advanced Polymer Systems, Inc. Procede et composition servant a traiter des maladies de la peau au moyen de vitamine k
WO1997039733A1 (fr) * 1996-04-23 1997-10-30 The Procter & Gamble Company Methodes de traitement et d'amelioration de l'aspect de la peau au moyen d'un compose a la vitamine b¿3?

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALLPORT JENNIFER R ET AL: "A possible role for mono(ADP-ribosyl) transferase in the signalling pathway mediating neutrophil chemotaxis.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 42, no. 1, 1996, pages 99 - 106, XP009001943, ISSN: 0306-5251 *
GORIO A ET AL: "Endogenous mono-ADP-ribosylation in retina and peripheral nervous system. Effects of diabetes.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. UNITED STATES 1997, vol. 419, 1997, pages 289 - 295, XP009001944, ISSN: 0065-2598 *
MCLIGEYO S O ET AL: "DIABETIC ULCERS A CLINICAL AND BACTERIOLOGICAL STUDY", EAST AFRICAN MEDICAL JOURNAL, vol. 68, no. 3, 1991, pages 204 - 209, XP001120779, ISSN: 0012-835X *
See also references of WO9963982A1 *
UYEDA K ET AL: "KAPOSI SARCOMA-LIKE GRANULOMA ON DIAPER DERMATITIS A REPORT OF 5 CASES", ARCHIVES OF DERMATOLOGY, vol. 107, no. 4, 1973, pages 605 - 607, XP009001941, ISSN: 0003-987X *
WALLIS R A ET AL: "TRAUMATIC NEUROPROTECTION WITH INHIBITORS OF NITRIC OXIDE AND ADP-RIBOSYLATION", BRAIN RESEARCH, AMSTERDAM, NL, vol. 710, 1996, pages 169 - 177, XP002924679, ISSN: 0006-8993 *
WEIGERT ROBERTO ET AL: "Characterization of chemical inhibitors of brefeldin A-activated mono-ADP-ribosylation.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 22, 1997, pages 14200 - 14207, XP002224494, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO1999063982A1 (fr) 1999-12-16
AU4438399A (en) 1999-12-30
EP1085859A1 (fr) 2001-03-28
CA2329160A1 (fr) 1999-12-16
JP2002517436A (ja) 2002-06-18

Similar Documents

Publication Publication Date Title
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
EP1536804A4 (fr) Ester 3'-l-valine de ?-d-2'-c-methyl-ribofuranosyl cytidine pour le traitement d'infections par des flaviviridae
EP1420797A4 (fr) Therapie dermique mettant en oeuvre des derives de phosphate d'agents de transfert electroniques
ID30062A (id) Alanog-analog benzopiran tersubstitusi untuk pengobatan radang
DE69631330D1 (de) C-4' modifizierte adenosinkinaseinhibitoren
EP0883398A4 (fr) Procede d'inhibition du photoviellissement de la peau
FI944523A0 (fi) Papilloomaviruksen inhibitio vastinjuosteoligonukleotidilla
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
EP1133273A4 (fr) Procede d'inhibition des lesions dentaires de resorption
NO20010053L (no) Farnesyl proteintransferaseinhibitorer for behandling av artropatier
DE69413815D1 (de) Inhibierung des Haarwuchses
NO20010490L (no) Inhibisjon av ''graft-versus-host''-sykdom
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
EP1126850A4 (fr) Traitement des affections de la retine
BR9607427A (pt) Inibiçao de angiogêne usando interleucina 12
FI951601A0 (fi) Rasgeenin antisens-oligonukleotidi-inhibitio
MA25501A1 (fr) Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.
EP0862460A4 (fr) Procedes de reduction de l'inhibition du remodelage neuronal induit par l'apolipoproteine e4
FR2775682B1 (fr) Traitement d'effluents aqueux par injection d'anhydride carbonique
IT1271567B (it) Procedimento per l'ulteriore trattamento di salcicce
FI953170A7 (fi) Oligunokleotidit isoprenyyliproteiinitransferaasin ilmentämisen inhibiboimiseksi
EP0973533A4 (fr) Methodes d'inhibition de cytotoxicite bacterienne
IT1288399B1 (it) Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
DE69308762D1 (de) Behandlung des Muskulschwunds
EP0824341A4 (fr) Prevention des pertes de dnets par l'administration d'alendronate ou de ses sels

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/37 B

Ipc: 7A 61K 31/70 B

Ipc: 7A 61K 31/35 B

Ipc: 7A 61K 31/455 B

Ipc: 7A 61K 31/12 B

Ipc: 7A 61K 31/045 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030113

17Q First examination report despatched

Effective date: 20030429

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031111